UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemoprevention of prostate cancer: current status and future directions

Cancer and metastasis reviews, 2002, Vol.21 (3-4), p.297

Lieberman, Ronald

2002

Volltextzugriff (PDF)

The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial

Cancer epidemiology, biomarkers & prevention, 2008-02, Vol.17 (2), p.292-299

2008

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Cancer epidemiology, biomarkers & prevention, 2003-11, Vol.12 (11), p.1213-1221

2003

Volltextzugriff (PDF)

Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg

American journal of therapeutics, 2012-11, Vol.19 (6), p.395-396

Lieberman, Ronald

2012

Volltextzugriff (PDF)

Progress in the treatment of peripheral T-cell lymphomas: an orphan no more

American journal of therapeutics, 2013-09, Vol.20 (5), p.460-462

Lieberman, Ronald

2013

Volltextzugriff (PDF)

The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks

American journal of therapeutics, 2013-03, Vol.20 (2), p.128-131

Lieberman, Ronald

2013

Volltextzugriff (PDF)

Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia

Cancer epidemiology, biomarkers & prevention, 2006-08, Vol.15 (8), p.1479-1484

2006

Volltextzugriff (PDF)

Progress in Cancer Chemoprevention

Annals of the New York Academy of Sciences, 1999-10, Vol.889 (1), p.1-13

1999

Volltextzugriff (PDF)

Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer

American journal of therapeutics, 2004-11, Vol.11 (6), p.501-506

Lieberman, Ronald

2004

Volltextzugriff (PDF)

Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer

American journal of therapeutics, 2009-11, Vol.16 (6), p.477-479

Lieberman, Ronald

2009

Volltextzugriff (PDF)

Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1754-1763

2006

Volltextzugriff (PDF)

A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia

Clinical cancer research, 2004-11, Vol.10 (22), p.7583-7591

2004

Volltextzugriff (PDF)

Changes in Serum Proteomic Patterns by Presurgical α-Tocopherol and l-Selenomethionine Supplementation in Prostate Cancer

Cancer epidemiology, biomarkers & prevention, 2005-07, Vol.14 (7), p.1697-1702

2005

Volltextzugriff (PDF)

Prostate cancer chemoprevention: Strategies for designing efficient clinical trials

Urology (Ridgewood, N.J.), 2001-04, Vol.57 (4), p.224-229

Lieberman, Ronald

2001

Volltextzugriff (PDF)

Lycopene in cancer prevention and treatment

American journal of therapeutics, 2008-01, Vol.15 (1), p.66-81

2008

Volltextzugriff (PDF)

Progress in Cancer chemoprevention : Development of diet-derived chemopreventive agents

The Journal of nutrition, 2000-02, Vol.130 (2), p.467S-471S

2000

Volltextzugriff (PDF)

Mycophenolate mofetil : a report of the consensus panel

Therapeutic drug monitoring, 1995-12, Vol.17 (6), p.690-699

1995

Volltextzugriff (PDF)

ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER

The Journal of urology, 2005-08, Vol.174 (2), p.539-546

2005

Volltextzugriff (PDF)

Evolving strategies for prostate cancer chemoprevention trials

World journal of urology, 2003-05, Vol.21 (1), p.3-8

Lieberman, Ronald

2003

Volltextzugriff (PDF)

Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development

Urology (Ridgewood, N.J.), 2001-08, Vol.58 (2), p.83-90

Lieberman, Ronald

2001

Volltextzugriff (PDF)

Cardiovascular safety monitoring during oncology drug development and therapy

American journal of therapeutics, 2014-11, Vol.21 (6), p.512-522

2014

Volltextzugriff (PDF)

Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine

Journal of clinical pharmacology, 1995-04, Vol.35 (4), p.368-373

1995

Volltextzugriff (PDF)

Chemoprevention of prostate cancer: Current status and future directions : Cancer chemoprevention

Cancer and metastasis reviews, 2002, Vol.21 (3-4), p.297-309

LIEBERMAN, Ronald

2002

Volltextzugriff (PDF)

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Clinical lung cancer, 2015-03, Vol.16 (2), p.92-99

2015

Volltextzugriff (PDF)

Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.273-273

2012

Volltextzugriff (PDF)

1 – 25 von 299

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(264)
Mit Volltextzugriff
(221)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(298)

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Humans
(154)
Life Sciences & Biomedicine
(150)
Male
(81)
Biological And Medical Sciences
(70)
Medical Sciences
(64)
Female
(61)
Middle Aged
(46)
Adult
(42)
Aged
(41)
Pharmacology. Drug Treatments
(32)
Oncology
(23)
Pharmacology & Pharmacy
(23)
Alzheimer Disease - Genetics
(22)
Animals
(21)
Neurosciences & Neurology
(21)
Aged, 80 And Over
(20)
Clinical Neurology
(18)
Genome-Wide Association Study
(18)
Prostatic Neoplasms - Prevention & Control
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Chemoprevention of prostate cancer: current status and future directions

The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg

Progress in the treatment of peripheral T-cell lymphomas: an orphan no more

The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks

Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia

Progress in Cancer Chemoprevention

Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer

Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer

Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model

A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia

Changes in Serum Proteomic Patterns by Presurgical α-Tocopherol and l-Selenomethionine Supplementation in Prostate Cancer

Prostate cancer chemoprevention: Strategies for designing efficient clinical trials

Lycopene in cancer prevention and treatment

Progress in Cancer chemoprevention : Development of diet-derived chemopreventive agents

Mycophenolate mofetil : a report of the consensus panel

ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER

Evolving strategies for prostate cancer chemoprevention trials

Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development

Cardiovascular safety monitoring during oncology drug development and therapy

Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine

Chemoprevention of prostate cancer: Current status and future directions : Cancer chemoprevention

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results

Suchergebnisse filtern